Order Article Reprints

Nimma R, Kalvala AK, Patel N, Surapaneni SK, Sun L, Singh R, Nottingham E, Bagde A, Kommineni N, Arthur P, et al. Combined Transcriptomic and Proteomic Profiling to Unravel Osimertinib, CARP-1 Functional Mimetic (CFM 4.17) Formulation and Telmisartan Combo Treatment in NSCLC Tumor Xenografts. Pharmaceutics. 2022; 14(6):1156. https://doi.org/10.3390/pharmaceutics14061156

Nimma, Ramesh, Anil Kumar Kalvala, Nilkumar Patel, Sunil Kumar Surapaneni, Li Sun, Rakesh Singh, Ebony Nottingham, Arvind Bagde, Nagavendra Kommineni, Peggy Arthur, and et al. 2022. "Combined Transcriptomic and Proteomic Profiling to Unravel Osimertinib, CARP-1 Functional Mimetic (CFM 4.17) Formulation and Telmisartan Combo Treatment in NSCLC Tumor Xenografts" Pharmaceutics 14, no. 6: 1156. https://doi.org/10.3390/pharmaceutics14061156

Nimma, R., Kalvala, A. K., Patel, N., Surapaneni, S. K., Sun, L., Singh, R., Nottingham, E., Bagde, A., Kommineni, N., Arthur, P., Nathani, A., Meckes, D. G., Jr., & Singh, M. (2022). Combined Transcriptomic and Proteomic Profiling to Unravel Osimertinib, CARP-1 Functional Mimetic (CFM 4.17) Formulation and Telmisartan Combo Treatment in NSCLC Tumor Xenografts. Pharmaceutics, 14(6), 1156. https://doi.org/10.3390/pharmaceutics14061156